新一代国产流感抗病毒口服药上市

Core Viewpoint - The approval of the antiviral oral drug Marcilosavir (brand name: Jikeshou) by the National Medical Products Administration marks a significant advancement in the treatment of influenza, specifically for healthy adult patients with uncomplicated influenza A and B [1] Group 1: Product Approval - Marcilosavir is developed by Zhengxiang Pharmaceutical and is a new generation polymerase acidic protein (PA) endonuclease inhibitor [1] - The drug exhibits broad-spectrum antiviral properties against influenza viruses, including both A and B types, as well as highly pathogenic avian influenza viruses [1]